JP2019527729A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527729A5
JP2019527729A5 JP2019522614A JP2019522614A JP2019527729A5 JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5 JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5
Authority
JP
Japan
Prior art keywords
formulation
polypropylene glycol
therapeutic
ppm
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/041691 external-priority patent/WO2018013673A1/en
Publication of JP2019527729A publication Critical patent/JP2019527729A/ja
Publication of JP2019527729A5 publication Critical patent/JP2019527729A5/ja
Pending legal-status Critical Current

Links

JP2019522614A 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤 Pending JP2019527729A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662361793P 2016-07-13 2016-07-13
US62/361,793 2016-07-13
PCT/US2017/041691 WO2018013673A1 (en) 2016-07-13 2017-07-12 Stabilizing excipients for therapeutic protein formulations

Publications (2)

Publication Number Publication Date
JP2019527729A JP2019527729A (ja) 2019-10-03
JP2019527729A5 true JP2019527729A5 (enExample) 2020-08-06

Family

ID=60941865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522614A Pending JP2019527729A (ja) 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤

Country Status (6)

Country Link
US (4) US10279048B2 (enExample)
EP (1) EP3484520A4 (enExample)
JP (1) JP2019527729A (enExample)
KR (1) KR20190027878A (enExample)
CA (1) CA3030422C (enExample)
WO (1) WO2018013673A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2019036619A1 (en) * 2017-08-18 2019-02-21 Reform Biologics, Llc STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
KR20230018549A (ko) * 2018-03-07 2023-02-07 코메라 라이프 사이언시스, 인코포레이티드 단백질 제형을 위한 부형제 화합물
WO2019180561A1 (en) 2018-03-20 2019-09-26 Mankind Pharma Ltd. Stable pharmaceutical composition of vasopressin
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
EP3852723B1 (en) 2018-09-20 2025-11-05 ACADIA Pharmaceuticals Inc. Stable intranasal formulations of carbetocin
AU2019345313A1 (en) 2018-09-20 2021-03-18 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
WO2020213682A1 (ja) * 2019-04-19 2020-10-22 富士フイルム和光純薬株式会社 細胞外小胞の保存安定化剤及び保存安定化方法
EP4178529A1 (en) * 2020-07-07 2023-05-17 F. Hoffmann-La Roche AG Alternative surfactants as stabilizers for therapeutic protein formulations
TW202408580A (zh) * 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(二)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510633C3 (de) 1975-03-12 1978-07-13 Boehringer Mannheim Gmbh, 6800 Mannheim Diagnostisches Mittel zum Nachweis von Eiweiß in Körperflüssigkeiten und dafür geeignete Indikatorfarbstoffe
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US6039977A (en) 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
CA2439097C (en) * 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
US7041088B2 (en) 2002-10-11 2006-05-09 Ethicon, Inc. Medical devices having durable and lubricious polymeric coating
DE10325198B4 (de) 2003-06-04 2007-10-25 Clariant Produkte (Deutschland) Gmbh Verwendung von alkoxylierten vernetzten Polyglycerinen als biologisch abbaubare Emulsionsspalter
US8025915B2 (en) 2006-01-11 2011-09-27 Schott Ag Method of preparing a macromolecule deterrent surface on a pharmaceutical package
WO2009055427A2 (en) 2007-10-22 2009-04-30 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
WO2009065126A2 (en) 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
AU2010277559B2 (en) * 2009-07-31 2016-08-11 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
CA2792965A1 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable aqueous mia/cd-rap formulations
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
MY161390A (en) 2010-06-24 2017-04-14 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
WO2012135035A1 (en) * 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
SG11201407812SA (en) 2012-05-31 2014-12-30 Agency Science Tech & Res Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
JP2015526471A (ja) * 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6026002B2 (ja) 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
HK1220120A1 (zh) 2013-03-15 2017-04-28 Ansun Biopharma, Inc. 制造注射蛋白质微粒悬浮液的方法
CN105229030A (zh) * 2013-04-22 2016-01-06 葛莱高托普有限公司 用具有低岩藻糖基化的抗-egfr抗体的抗-癌治疗
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Similar Documents

Publication Publication Date Title
JP2019527729A5 (enExample)
EP2525787B1 (en) Liquid formulations for long-acting g-csf conjugate
Rajoria et al. In-situ gelling system: a novel approach for ocular drug delivery
US9682149B2 (en) Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase
JP2016530321A5 (ja) イオン性液体を含有する注射用液状タンパク質製剤およびその使用
KR20140091707A (ko) 크실리톨로 안정화된 에타너셉트 제형
JP7223712B2 (ja) 安定なペプチド組成物
KR20190027878A (ko) 치료 단백질 제제용 안정화 부형제
CN104159614A (zh) TNF-α抗体的药物制剂
US20160120946A1 (en) Compositions comprising gc-macrophage activating factor and uses thereof
JP2019525951A5 (enExample)
JP2019532949A (ja) 耐熱保護剤、室温で保存可能な豚コレラ生ワクチンの製造方法及びその使用
AU2013336206A1 (en) Stable pharmaceutical composition of peginterferon alpha-2b
EP4003290B1 (en) Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
JPWO2000000221A1 (ja) 水溶性乾燥組成物
CN105412942A (zh) 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
CN115518151A (zh) 一种人类免疫缺陷病毒中和抗体制剂及其用途
US11229702B1 (en) High concentration formulations of adalimumab
CN101376022A (zh) 含聚乙二醇降纤酶的药物组合物
WO1999045953A1 (fr) Compositions contenant un cofacteur ii de l'heparine et techniques de stabilisation
CN110799188A (zh) 基于托品酰胺的眼用制剂
HK1175721A (en) Liquid formulations for long-acting g-csf conjugate
JPWO2014115882A1 (ja) タンパク質を安定化させたゲル状製剤
JPH07242562A (ja) 顆粒球コロニー刺激因子含有直腸投与製剤